Cross-reactivity studies and predictive modeling of "bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays

Clinical Toxicology

Volumn 51, Issue 2, 2013, Pages 83-91

  Petrie, M ^a,b   Lynch, K L ^a   Ekins, S ^c   Chang, J S ^b   Goetz, R J ^d,e   Wu, A H B ^a   Krasowski, M D ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c Collaborations in Chemistry ^*  (United States)

^d Cincinnati Drug and Poison Information Center   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Molecular conformations; Molecular models; Similarity; Substance abuse detection

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CATHINONE; MESCALINE; METHAMPHETAMINE; METHCATHINONE; PIPERAZINE;

ACCURACY; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CROSS REACTION; DRUG TOXICITY; HYDROGEN BOND; HYDROPHOBICITY; IMMUNOASSAY; MOLECULAR MODEL; PREDICTIVE VALUE; SCREENING TEST; SUBSTITUTION REACTION; TOXICITY TESTING; X RAY CRYSTALLOGRAPHY;

AMPHETAMINES; ANTIBODY SPECIFICITY; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS REACTIONS; CRYSTALLOGRAPHY, X-RAY; IMMUNOASSAY; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PREDICTIVE VALUE OF TESTS; ROC CURVE; STREET DRUGS; SUBSTANCE ABUSE DETECTION;

EID: 84873644144     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2013.768344     Document Type: Article

References (43)

1. Peters FT, Martinez-Ramirez JA. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 2010; 32: 532-539.
2. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49: 705-719.
3. Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med 2011; 365: 967-968.
4. W inder G S, Stern N, Hosanagar A. Are "Bath Salts" the next generation of stimulant abuse? J Subst Abuse Treat 2012.
5. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of synthetic cathinones in Schedule I. Final Order. Fed Regist 2011; 76: 65371-65375.
6. Administration USDE. Congress agrees to add 26 synthetic drugs to Controlled Substances Act. 2012 [updated 2012; cited]; Available from: http://www.justice.gov/dea/pubs/pressrel/pr061912.html.
7. Apollonio LG, Whittall IR, Pianca DJ, Kyd JM, Maher WA. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine. J Anal Toxicol 2007; 31: 208-213.
8. Kerrigan S, Mellon M B, Banuelos S, Arndt C. E valuation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines. J Anal Toxicol 2011; 35: 444-451.
9. Nakanishi K, Miki A, Zaitsu K, Kamata H, Shima N, Kamata T, et al. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View, and the Emit(R) assays for use in drug enforcement. Forensic Sci Int 2012; 217: 174-181.
10. Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824: 123-131.
11. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006; 36: 709-723.
12. Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397: 1225-1233.
13. Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab 2005; 6: 259-274.
14. Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, et al. Determination of a newly encountered designer drug "p- methoxyethylamphetamine" and its metabolites in human urine and blood. Forensic Sci Int 2008; 177: 77-84.
15. Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009; 9: 5.
16. Krasowski MD, Siam MG, Iyer M, Pizon AF, Giannoutsos S, Ekins S. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem 2009; 55: 1203-1213.
17. Krasowski MD, Siam MG, Iyer M, Ekins S. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit 2009; 31: 337-344.
18. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006; 24: 805-815.
19. Willett P. Similarity-based approaches to virtual screening. Biochem Soc Trans 2003; 31: 603-606.
20. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000; 43: 4759-4767.
21. Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42: 5100-5109.
22. Zhang Q, Muegge I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J Med Chem 2006; 49: 1536-1548.
23. Wang QC, Shang Y, Xu D. Improving a consensus approach for protein structure selection by removing redundancy. IEEE/ACM Trans Comput Biol Bioinform 2011; 8: 1708-1715.
24. Ekins S, Mestres J, Testa B. Insilico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 2007; 152: 21-37.
25. Li J, Ehler T, Sutter J, Varma-O'Brien S, Kirchmair J. CAESAR: a new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J Chem Inf Model 2007; 47: 1923-1932.
26. Astorga B, Ekins S, Morales M, Wright S H. Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther 2012; 341: 743-755.
27. Diao L, Ekins S, Polli JE. Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm 2010; 7: 2120-2131.
28. Fidler AE, Holland PT, Reschly EJ, Ekins S, Krasowski MD. Activation of a tunicate (Ciona intestinalis) xenobiotic receptor orthologue by both natural toxins and synthetic toxicants. Toxicon 2011; 59: 365-372.
29. Celikel R, Peterson EC, Owens SM, Varughese KI. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Sci 2009; 18: 2336-2345.
30. Dickson AJ, Vorce SP, Holler JM, Lyons TP. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples. J Anal Toxicol 2008; 34: 464-469.
31. Dickson AJ, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 2010; 34: 162-168.
32. Soares ME, Carvalho M, Carmo H, Remiao F, Carvalho F, Bastos ML. Simultaneous determination of amphetamine derivatives in human urine after SPE extraction and HPLC-UV analysis. Biomed Chromatogr 2004; 18: 125-131.
33. Shulgin A, Shulgin A. PIHKAL: A Chemical Love Story. Berkeley, CA: Transform Press; 1991.
34. Shulgin A, Shulgin A. TIHKAL: The Continuation. Berkeley, CA: Transform Press; 1997.
35. Christophersen AS. Amphetamine designer drugs-an overview and epidemiology. Toxicol Lett 2000; 112-113: 127-131.
36. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-181.
37. Kortagere S, Krasowski MD, Ekins S. The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci 2009; 30: 138-147.
38. Kristam R, Gillet VJ, Lewis RA, Thorner D. Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst. J Chem Inf Model 2005; 45: 461-476.
39. Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA. Crystal structure of a cocaine-binding antibody. J Mol Biol 2001; 311: 9-15.
40. Pozharski E, Moulin A, Hewagama A, Shanafelt A B, Petsko G A, Ringe D. Diversity in hapten recognition: structural study of an anticocaine M82G2. J Mol Biol 2005; 349: 570-582.
41. Pozharski E, Wilson M A, Hewagama A, Shanafelt A B, Petsko G, Ringe D. Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine. J Mol Biol 2004; 337: 691-697.
42. Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS. Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J Biol Chem 1998; 273: 28576-28582.
43. Monnet C, Bettsworth F, Stura EA, Le Du MH, Menez R, Derrien L, et al. Highly specific anti-estradiol antibodies: structural characterisation and binding diversity. J Mol Biol. 2002; 315: 699-712.